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Abstract It is now evident that elevated circulating levels of
triglycerides in the non-fasting state, a marker for triglyceride
(TG)-rich remnant particles, are associated with increased risk
of premature cardiovascular disease (CVD). Recent findings
from basic and clinical studies have begun to elucidate the
mechanisms that contribute to the atherogenicity of these
apoB-containing particles. Here, we review current knowl-
edge of the formation, intravascular remodelling and catabo-
lism of TG-rich lipoproteins and highlight (i) the pivotal
players involved in this process, including lipoprotein lipase,
glycosylphosphatidylinositol HDL binding protein 1
(GPIHBP1), apolipoprotein (apo) C-II , apoC-III ,
angiopoietin-like protein (ANGPTL) 3, 4 and 8, apoA-V and
cholesteryl ester transfer protein; (ii) key determinants of tri-
glyceride (TG) levels and notably rates of production of very-
low-density lipoprotein 1 (VLDL1) particles; and (iii) the
mechanisms which underlie the atherogenicity of remnant
particles. Finally, we emphasise the polygenic nature of mod-
erate hypertriglyceridemia and briefly discuss modalities for
its clinical management. Several new therapeutic strategies to
attenuate hypertriglyceridemia have appeared recently, among
which those targeted to apoC-III appear to hold considerable
promise.
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Introduction
Whether plasma triglycerides, or more specifically, the lipo-
protein particles in which they are transported between sites of
absorption, lipolysis and remodelling and catabolism consti-
tute an independent risk factor for CVD has been the subject
of debate for decades [1]. Significant progress has been made
of late in resolving this question as a result of three elements:
firstly, the availability of prospective data focusing on the
relationship between circulating TG levels and cardiovascular
risk in large cohorts, secondly, observations made in the post-
prandial, non-fasting period, allowing analysis of this relation-
ship over a substantially greater range of TG concentrations as
compared to the fasting state and thirdly, analytical ap-
proaches which allow an estimation of the cholesterol burden
carried in potentially atherogenic remnant particles [2–5, 6•].
Thus, accumulating evidence demonstrates a strong correla-
tion between the risk of CVD and both non-fasting
(postprandial) and fasting plasma TG levels. Furthermore,
large prospective epidemiologic studies focused on non-
fasting TG in response to normal food intake have demonstrat-
ed significant associations between increased CVD events
with elevated concentrations of non-fasting TG [2, 3, 7].
Indeed, a meta-analysis of 17 prospective studies with 2900
CHD endpoints revealed that an increment of 1 mmol/L in
fasting TG levels was associated with a 14 % increase in
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CVD risk [5]. However, this strong correlation is often lost or
attenuated in multivariate analysis, principally as a conse-
quence of the strong link between hypertriglyceridemia and
other cardiovascular risk factors such as low high-density li-
poprotein (HDL) cholesterol, obesity and insulin resistance [8,
9•]. Further support for a causative role of triglyceride-rich
lipoproteins (TRLs) in CVD arises from genetic studies [4,
10–12]; such studies equally indicate that remnant particles,
which represent the partially degraded products of TRLs (i.e.
chylomicrons and very-low-density lipoprotein (VLDL)),
play a key role in the pathophysiology of atherosclerotic vas-
cular disease.
Hypertriglyceridemia is generally defined and diagnosed
as fasting plasma TG>1.7 mmol/L or >150 mg/dL and is
the consequence of environmental, behavioural and genetic
factors, among which lifestyle is prominent (alcohol use,
smoking, a high carbohydrate diet and obesity) [13••].
Severe hypertriglyceridemia with plasma TG levels
>10 mol/L (885 mg/dL) is typically of genetic origin, notably
in the pediatric age group, and is associated with elevated risk
of pancreatitis [14]. Further understanding of the pathobiology
which underlies the atherogenicity of TRLs and their remnants
will undoubtedly enable us to identify novel therapeutic tar-
gets; the translation of such targets into innovative therapeutic
agents may significantly decrease cardiovascular risk in large
numbers of hypertriglyceridemic individuals who currently
remain at high risk despite optimal treatment according to
current guideline recommendations.
Production and Intravascular Metabolism
of Triglyceride-Rich Lipoproteins and Remnants
Triglycerides represent the transport module for fatty acids
which provide an essential source of energy upon oxidation
in mitochondria. A major source of TG is derived from dietary
fat consumption. Dietary TGs are transported in intestinally
derived apolipoprotein (apo) B48-containing chylomicrons,
which enter the systemic circulation through the lymphatic
system and target the heart as the first organ for delivery of
fatty acids to fulfil energy requirements. The liver plays a
cental role in TG homeostasis and maintains a steady state
between TG synthesis, secretion and oxidation. In contrast
to adipose tissue, the liver does not serve as an organ for TG
storage under normal physiologic conditions. The liver can
take up fatty acids derived from lipolysis in adipose tissue or
from circulating lipoproteins but may equally synthesise fatty
acids from carbohydrates in the process of de novo lipogene-
sis. In the liver, fatty acids can be partly stored as TG in lipid
droplets or oxidised to generate energy in mitochondria in the
process of beta-oxidation or packaged in apo B100-containing
VLDL particles and secreted into the systemic circulation
where they serve as a source for energy for peripheral tissues.
The molecular pathway involved in the packaging of TG into
both chylomicron and VLDL particles is remarkably similar,
involving microsomal triglyceride transfer protein (MTTP) as
described in detail elsewhere [15, 16].
Triglycerides cannot pass through cell membranes freely.
Consequently, intravascular lipolysis is an essential process
for release of free fatty acids, which can then be taken up via
specific fatty acid transporters or other yet unknown mecha-
nisms. The underlying mechanism is still only partly under-
stood, but identification of some of the key proteins involved
has allowed progress in our understanding. Lipoprotein lipase
(LPL) is the key enzyme which drives TG hydrolysis along
the luminal surface of capillaries, whereas the recently identi-
fied protein glycosylphosphatidylinositol HDL binding pro-
tein 1 (GPIHBP1) provides the platform to allow lipolysis to
occur at the endothelial cell surface [17, 18]. Lipoprotein li-
pase is synthesised in macrophages, adipocytes and myocytes
and must be transferred to the luminal site of the endothelial
cell to become active, a process which is facilitated by
GPIHBP1 [18, 19]. Strict regulation of LPL production and
activity is critical in different tissues and organs. LPL can be
regulated at the level of transcription by both peroxisome
proliferator-activated receptor (PPAR)α and PPARγ through
binding to a PPRE element in the 5′ regulatory region of the
LPL gene [20, 21]. PPARα is intimately involved in lipid
metabolism in the liver, whereas PPARγ is more closely in-
volved in adipose tissue lipid homeostasis thereby regulating
LPL action in a tissue-specific manner. More recently, differ-
ent microRNAs (miR29-a, 497b, 1277, 410) have been found
to be involved in posttranslational regulation of LPL; the exact
mechanism(s) has not as yet been elucidated [22, 23]. Both
nutritional (fasting vs fed state) and hormonal status play cen-
tral roles in the regulation of LPL expression in adipose tissue.
In fed conditions, LPL activity is high due to the effect of
insulin, thereby resulting in increased uptake of fatty acids.
Interestingly, LPL is more strictly regulated in heart and skel-
etal muscle since these tissues need a continuous supply of
fatty acids for energy production [24].
Regulation of the Lipolytic Process
In vivo LPL action is regulated by several proteins including
apolipoprotein (apo) C-II, apoA-V, apoC-III and angiopoietin-
like protein (ANGPTL) 3, 4 and 8 [25] (Fig. 1). ApoC-II is a
79 amino acid peptide of hepatic origin containing a C-
terminal domain involved in LPL activation and an N-
terminal domain involved in lipid binding. Very little is known
of the regulation of apoC-II synthesis. ApoC-II circulates in
plasma on TG-rich lipoprotein particles as well as on HDL
and is the rate-limiting protein required for normal LPL activ-
ity to occur. Patients with complete loss-of-function mutations
in APOC2 have severe hypertriglyceridemia similar to LPL
deficiency [26]. On the other hand, increased plasma apoC-II
levels are associated with increased plasma TG levels
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suggesting that a surplus may have an inhibitory effect on LPL
function. ApoC-II may be important for guiding TG-rich lipo-
proteins to the active site of LPL at the endothelial cell surface
[27, 28]. The proposed working model for apoC-II involves a
mechanical process occurring during hydrolysis of lipoprotein
TG and results in increased surface pressure with concomitant
conformational change in apoC-II structure, followed by the
release of an apoC-II-phosphatidyl choline complex to HDL
[29]. The amino acid residues tyr63, ile66, asp69 and gln70 in
the C-terminal helix of apoC-II are essential for LPL activa-
tion and have now been used to create an apoC-II mimetic
peptide that promotes lipolysis on TG-rich lipoproteins by
LPL and may represent a new therapeutic target [30, 31].
ApoC-III is a potent inhibitor of LPL function and is a 99
amino acid protein containing three sialic acid residues; it is
synthesised mainly in the liver and to a small extent in the
intestine. Different transcription factors may regulate APOC3
gene expression such as PPARα and Fox01 [20, 32]. ApoC-
III circulates on TG-rich lipoprotein particles as well as on
HDL [33]. The apoC-III protein undergoes O-linked glycosyl-
ation by GALNT2 resulting in the presence of three isoforms:
apoC-III 0, 1 and 2, which is impacting on apoC-III function
[34]. Genetic studies have provided insight into the function
of apoC-III. With respect to the potential relationship of cir-
culating apoC-III levels to cardiovascular risk, a null mutation,
p.R19X (rs56353203), was found to be associated with low
plasma TG levels and attenuated subclinical atherosclerosis in
the Amish population [35, 36]. Additional evidence was pro-
vided in a number of epidemiological studies showing the
causal relationship between genetic variants in APOC3, plas-
ma TG and CVD risk [37–39]. ApoC-III is now recognised as
a multifaceted protein involved in different metabolic process-
es related to TG homeostasis. Firstly, apoC-III may inhibit
hepatic clearance of TG-rich remnant particles by interfering
with receptor binding sites [33]. Secondly, apoC-III has been
recognised to inhibit LPL-mediated lipolysis in vitro; kinetic
studies in human subjects do not however favour this concept
[40]. Apparently, the ratio of apoC-III to apoC-II molecules on
the surface of VLDL particles is the main determinant for LPL
inhibition to occur. In vitro studies have shown that apoC-III/
apoC-II ratios >5.0 are effective in inhibiting LPL action [41],
a molar ratio which does not occur in human physiology.
Finally, recent clinical trials in hypertriglyceridemic LPL-
deficient patients using an allele-specific oligonucleotide
(ASO) against apoC-III are in line with the concept that
apoC-III has a major role in the hepatic uptake of remnant
particles [42]. Thus, apoC-III emerges as an important drug
target for reducing residual cardiovascular risk in
hypertriglyceridemic subjects [43].
ApoA-V is a 366 amino acid protein primarily of hepatic
origin. Circulating plasma apoA-V concentrations are very low
whichmeans that at most only 4% of VLDL particles carry one
apoA-V molecule [44]. Despite such low abundance, evidence
supporting an essential role for apoA-V in TG metabolism is
accumulating. Rare variants in or close to the APOA5 gene
locus are consistently associated with plasma TG levels and
risk for CVD [45, 46]. However, plasma apoA-V levels are
positively associated with plasma TG in humans, an observa-
tion which to date has not been fully understood [44, 47, 48].
Most studies on apoA-V function have been performed in mice
overexpressing human apoA-V or in in vitro models using
apoA-V liposomes [49]. In all of these models, apoA-V con-
centration is elevated in comparison to the physiological con-
centrations typically seen in humans. Moreover, the physiolog-
ical context in which apoA-V is functional, i.e. in the presence
of apoC-II, apoC-III or apoE on the same lipoprotein particle,
and which all compete for similar functions, is missing.
Interestingly, injection of apoA-V rHDL into Apoa5−/− mice
induces a rapid decline in plasma TG levels whereas a similar
injection inGpihbp1−/−mice had no effect [50], suggesting that
apoA-V might be involved in binding of TG-rich lipoproteins
to GPIHBP1, thereby allowing LPL-mediated TG hydrolysis to
proceed [51]. Whether apoA-V is involved in LPL-mediated
TG lipolysis in humans has not yet been established.
Fig. 1 LPL is synthesised in
parenchymal cells in muscle and
adipose tissue and then
transported to the endothelial cell
surface. LPL-mediated TG
lipolysis at this surface is the first
essential step in TG homeostasis.
TGs are hydrolysed by LPL
bound to GPIHBP1 in a process
that is dependent on apoC-II.
ApoC-III and apoA-Vare
potential inhibitors of LPL-
mediated lipolysis. Upon TG
hydrolysis, free fatty acids are
taken up by surrounding tissues
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ANGPTL3, 4 and 8 have been implicated in TG homeo-
stasis. ANGPTL proteins contain a signal peptide, an N-
terminal coiled-coil domain and a C-terminal fibrinogen-like
domain [52]. ANGPTL4 is produced in adipose tissue, where-
as ANGPTL3 is produced in the liver and ANGPTRL8 in
both adipose tissue and the liver [53]. ANGPTL4 expression
is increased under fasting conditions, whereas ANGPTL8
levels are increased in the fed state. ANGPTL3, 4 and 8 have
been implicated in LPL action. In fasting conditions, in which
ANGPTL4 expression in adipose tissue is upregulated, LPL
action may be suppressed by ANGPTL4, resulting in
rerouting of fatty acids towards other organs for supply of
energy. ANGPTL4 effectively inhibits LPL action by
converting the active dimer into an inactive monomer [54].
However, evidence has accumulated to show that ANGPTL4
could also act as a reversible, non-competitive inhibitor of
LPL [55]. Such inhibition occurs solely when LPL is in a
complex with ANGPTL4 and leads to restoration of LPL ac-
tivity upon dissociation of the complex. Alternatively,
ANGPTL4 may directly bind LPL that is bound to
GPIHBP1 and in this manner inactivate the protein,
whereafter dissociation from GPIHBP1 occurs [56].
Although the role of ANGPTL3 in regulation of lipolysis is
less well understood, mutations in the ANGPTL3 gene in
humans are associated with reduced TG and cholesterol
levels and elevated LPL activity [57]. ANGPTL3 is ac-
tivated by proteolytic cleavage, leading to the release of
the N-terminal domain, which has been shown to inhibit
LPL and therefore result in reduced TG clearance.
Recent data have emerged that ANGPTL8, also known
as betatrophin or lipasin and a paralog of ANGPTL3, is
able to interact with ANGPTL3, facilitating the cleavage
of its N-terminal domain and thereby regulating its ac-
tivity [58, 59]. In conclusion, all three ANGPTL iso-
forms are able to impact LPL activity and thereby lead
to altered plasma TG levels.
Determinants of Plasma Triglyceride Levels
and Heterogeneity of Triglyceride-Rich Lipoprotein
Particles
Very-low-density lipoprotein particles of hepatic origin can be
subdivided on the basis of their size and role in TG metabo-
lism; the larger, less dense particles are defined as VLDL1 (Sf
60–400) and the smaller as VLDL2 (Sf 20–60). Elevation of
levels of large TG-rich VLDL1 is the major determinant of
plasma TG concentrations in both normal and insulin-resistant
individuals [60]. Increased plasma concentrations of VLDL1
can result either from hepatic oversecretion and/or impaired
clearance of TRL remnants from the circulation [61, 62].
Hepatic oversecretion of VLDL1 particles is linked to in-
creased liver fat and hyperglycemia [61, 63, 64]. Increased
liver fat is equally associated with impaired suppression of
VLDL1 secretion and results in oversecretion of VLDL1 par-
ticles [64, 65]. Recent findings in in vivo kinetic studies have
shown that kinetic indices for VLDL1-TG catabolism are
stronger determinants of circulating plasma TG concentration
than kinetic parameters for the increased secretion of VLDL1
[66, 67•]. In particular, these studies revealed strong correla-
tions between the catabolism of VLDL1-TG levels and the
plasma concentration of apoC-III [66, 68]. The principal
mechanism underlying the impairment of the catabolism of
TRLs by apoC-III remains unclear, since apoC-III impairs
both intravascular lipolysis by LPL and LPL-independent
clearance of TRLs [69]. The significance of apoC-III in the
hepatic clearance of TRL was recently illustrated by the mark-
edly accelerated catabolism of TG-rich remnant particles in
human subjects with deficiency of apoC-III [70].
Remnants are generated when chylomicrons and VLDL
particles are remodelled during TG hydrolysis by LPL and
are concomitantly enriched in cholesteryl esters by the action
of the cholesteryl ester transfer protein (CETP). Thus, as TGs
are removed, remnant particles become enriched with
cholesteryl esters [71].
Subendothelial Accumulation of Atherogenic
Lipoproteins Induces Atherogenesis
Lipoproteins in the circulation normally flux into and out of
the arterial wall by transcytosis, a transport system in which
lipoproteins and other macromolecules are transported across
the endothelial cell in specialised clathrin-coated vesicles
(Fig. 2) [72]. The transcytosis pathway has not previously
attracted attention, but recent studies indicate that the process
is responsive to LDL levels in the blood [73–75]. The trans-
port vesicles are about 100 nm in diameter, and therefore, the
transcytotic transport system is restricted to lipoproteins
smaller than approximately 70 nm in diameter. Thus, larger
lipoproteins, such as chylomicrons and large VLDL particles,
cannot transverse the endothelium [76, 77]. This size limita-
tion explains why individuals with lipoprotein disorders in-
volving accumulation of large lipoproteins, such as chylomi-
crons in LPL-deficient patients, do not develop atherosclero-
sis. The capacity of the transcytotic transport system is very
high; indeed, it has been estimated that about 2500 transport
vesicles leave the plasma membrane every minute. Therefore,
it is not the influx of lipoproteins into the artery wall that is rate
limiting and thus determines the concentration of atherogenic
lipoproteins in the artery wall but rather the selective
subendothelial retention of lipoproteins in the artery wall
[78]. Such retention is mediated by ionic interactions between
positively charged residues in apoB and apoE on the athero-
genic lipoproteins [79–81] and negatively charged sugar and
sulphate groups in the glycosaminoglycan chains of the arte-
rial wall proteoglycans.
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Postprandial Hypertriglyceridemia and Atherogenicity
of Remnant Particles
For many years, accumulation of chylomicron and chy-
lomicron remnants in plasma was believed to be the
essential cause of postprandial hypertriglyceridemia
[82, 83]. However, it is now established that although
approximately 80 % of the increase in postprandial TG
is due to chylomicrons [84], approximately 80 % of the
increase in particle number is accounted for by VLDL
particles [85, 86]. The underlying reason is that chylo-
microns and VLDL particles are cleared from the circu-
lation by common pathways and therefore compete for
clearance [76], even if chylomicrons seem to be prefer-
entially cleared [87]. Increased secretion of liver-derived
VLDL is therefore causatively linked to postprandial
accumulation of chylomicron remnants [87]. As
discussed above, remnant particles contain significant
amount of cholesteryl esters and can enter the arterial
wall, even if their size results in attenuated transport
across the endothelium as compared to smaller LDL
particles. However, since each remnant particle contains
approximately 40 times more cholesterol compared with
LDL, elevated levels of remnants may lead to acceler-
ated atherosclerosis and CVD [77].
Interestingly, the importance of postprandial lipopro-
teins in the development of atherosclerotic vascular dis-
ease was initially proposed almost 70 years ago by
Moreton who wrote Bthe lipid particles must be as-
sumed to be retained and deposited from the plasma-
derived nutrient lymph stream which normally passes
from the lumen through the intramural structures to-
wards the adventitial venules and lymphatics. It may
be theorised that the increased particle size of the lipids
in sustained or alimentary hyperlipemia is the stimulus
to the phagocytosis in the intima by macrophages and
the formation of the typical foam cells^ [88, 89]. It is
now clear that Moreton’s work has not, until now, re-
ceived the attention it deserves.
Triglyceride-Rich Lipoproteins and Remnants
as Therapeutic Targets in Hypertriglyceridemia
As discussed above, recent epidemiological studies have un-
equivocally demonstrated that elevated levels of postprandial
TG and remnant particles are clinically significant risk factors
for CVD [2, 3, 6•]. Furthermore, postprandial TG concentra-
tions have been shown to be a superior risk predictor for CVD
than fasting TG [2, 3, 90]. Epidemiological data providing
insight into the frequency of mild to moderate hypertriglyc-
eridemia (approx. 150 to 800mg/dL) in the general population
as a function of age, gender and ethnicity is lacking; nonethe-
less, findings in the NHANES survey suggest that at least one
third of the US populat ion can be class i f ied as
hypertriglyceridemic [91]. The degree to which such hypertri-
glyceridemia reflects the impact of elements of dietary habits
and lifestyle relative to genetic factors is indeterminate. In this
context, it is however especially relevant that recent studies
from several laboratories suggest that mild to moderate
hypertriglyceridemia is frequently of polygenic origin, arising
as a result of a cumulative burden of common and rare variants
in more than 30 genes coding for proteins of the complex
lipolytic system, each of these polymorphisms generating pro-
teins with mildly attenuated biological activity [13••]. A ge-
netic score approach is therefore meaningful. Clearly then, an
emerging body of evidence supports the contention that, from
a therapeutic perspective, efforts to efficaciously reduce circu-
lating concentrations of TRLs and their remnants have be-
come critical.
Fig. 2 Transcytosis enable the influx of lipoproteins over the vessel wall.
This process is mediated by clathrin. The average diameter of these
transport vesicles are around 100 nm, which only allows transport of
lipoproteins with the size of 70 nm or smaller, thereby excluding
chylomicrons and large VLDL remnant particles. The average transport
speed is around 2500 vesicles per minute. The retention of lipoproteins in
the subendothelial space is mediated by the interaction between positively
charged residues on apoB and apoE and the negatively charged sulphate
groups in the glycosaminoglycans chains of HSPG expressed on the
vessel wall
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Management of Hypertriglyceridemia and New
Therapeutic Options
Following exclusion of secondary causes, treatment of mild to
moderate hypertriglyceridemia should follow guideline recom-
mendations, the initial step involving counselling on dietary
habits, smoking and exercise [92]. The objective in such indi-
viduals is clearly to diminish their cardiovascular risk. In the
event that pharmacotherapy is required, statins, fibrates and
omega-3 fatty acids are all effective agents for reduction of
TG levels, but only the use of statins is supported by a solid
evidence base derived from multiple randomised control inter-
vention trials [92].
New therapeutic options are currently under development
that have been based on genetic evidence for reduced cardio-
vascular risk in families with phenotypes involving markedly
diminished TG levels and rare causative monogenic muta-
tions. Of the candidate proteins involved, apoC-III stands
out as an elegant example. Indeed, a null mutation in human
APOC3 was discovered in 2008 in the Amish community in
the USA and found to provide apparent cardioprotection [35].
Abundant data now support the working hypothesis that
pharmacotherapeutic reduction in circulating apoC-III levels
may represent a valid target for hypotriglyceridemic therapy
and ultimately for reduction of cardiovascular risk and poten-
tially pancreatitis. Thus, loss-of-function mutations in APOC3
are associated with low TG levels and reduced risk of ische-
mic heart disease in two general population studies involving
more than 75,000 participants [37]. Similar findings were
made in the exome sequencing project [38].
As discussed above, apoC-III is a key factor on the surface of
TRL and is a critical modulator of the lipolytic activity of lipo-
protein lipase. Circulating levels of apoC-III are elevated howev-
er and of the order of 10–20 mg/dL, suggesting that hepatic
production of apoC-III may be more viable as a target compared
to a monoclonal antibody approach to remove apoC-III protein,
allowing maintenance of low plasma levels over extended pe-
riods of time [93]. It is in this context that the development of
anti-sense oligonucleotides targeted to the hepatic mRNA of
apoC3 hold considerable promise, as dose-dependent reductions
in TG levels of up to 80 % are attainable [94].
Conclusion
The number of patients with hypertriglyceridemia will grow
significantly over the coming years, partly due to the increase
in patients with diabetes mellitus type 2 and metabolic syn-
drome. Indeed, hypertriglyceridemia poses a major emerging
challenge for public health and requires adequate targeting. As
current therapies are not optimal for normalisation of elevated
TG levels, the development of novel therapeutic agents is
therefore warranted.
Compliance with Ethical Standards
Conflict of Interest M. Dallinga-Thie, J. Kroon and Jan Borén declare
that they have no conflict of interest.
John Chapman reports grants and personal fees from Pfizer and
Kowa, grants from CSL and personal fees from Amgen, Sanofi-
Regeneron and Astrazeneca.
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by any
of the authors.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular dis-
ease. Lancet. 2014;384:626–35.
2. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A.
Nonfasting triglycerides and risk of myocardial infarction,
ischemic heart disease, and death in men and women.
JAMA. 2007;298:299–308.
3. Bansal S, Buring JE, Rifai N, et al. Fasting compared with
nonfasting triglycerides and risk of cardiovascular events in wom-
en. JAMA. 2007;298:309–16.
4. Jorgensen AB, Frikke-Schmidt R, West AS, et al. Genetically ele-
vated non-fasting triglycerides and calculated remnant cholesterol
as causal risk factors for myocardial infarction. Eur Heart J.
2013;34:1826–33.
5. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor
for cardiovascular disease independent of high-density lipoprotein
cholesterol level: a meta-analysis of population-based prospective
studies. J Cardiovasc Risk. 1996;3:213–9.
6.• Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol
as a causal risk factor for ischemic heart disease. J AmColl Cardiol.
2013;61:427–36. This excellent paper describes the association
between plasma levels of remnant cholesterol and ischemic
heart disease in a large population cohort in Denmark and
illustrates the importance of remnant cholesterol in the
pathokogy of CVD.
7. Lindman AS, Veierod MB, Tverdal A, et al. Nonfasting triglycer-
ides and risk of cardiovascular death in men and women from the
Norwegian Counties Study. Eur J Epidemiol. 2010;25:789–98.
8. Emerging Risk Factors C, Di Angelantonio E, Gao P, et al. Lipid-
related markers and cardiovascular disease prediction. JAMA.
2012;307:2499–506.
9.• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich
lipoproteins and high-density lipoprotein cholesterol in patients at
high risk of cardiovascular disease: evidence and guidance for man-
agement. Eur Heart J. 2011;32:1345–61. This is an important
67 Page 6 of 9 Curr Cardiol Rep (2016) 18: 67
paper describing new guidelines with regard to the treatment of
patients with elevated levels of remnant cholesterol and
triglycerides.
10. Do R, Willer CJ, Schmidt EM, et al. Common variants associated
with plasma triglycerides and risk for coronary artery disease. Nat
Genet. 2013;45:1345–52.
11. HolmesMV, Asselbergs FW, Palmer TM, et al. Mendelian random-
ization of blood lipids for coronary heart disease. Eur Heart J.
2015;36:539–50.
12. Triglyceride Coronary Disease Genetics C, Emerging Risk Factors
C, Sarwar N, et al. Triglyceride-mediated pathways and coronary
disease: collaborative analysis of 101 studies. Lancet. 2010;375:
1634–9.
13.•• Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic na-
ture of hypertriglyceridaemia: implications for definition, diagnosis,
and management. Lancet Diabetes Endocrinol. 2014;2:655–66.
This is an overview of all the current knowledge.
14. Johansen CT, Hegele RA. Genetic bases of hypertriglyceridemic
phenotypes. Curr Opin Lipidol. 2011;22:247–53.
15. Hussain MM. Intestinal lipid absorption and lipoprotein formation.
Curr Opin Lipidol. 2014;25:200–6.
16. Cohen DE, Fisher EA. Lipoprotein metabolism, dyslipid-
emia, and nonalcoholic fatty liver disease. Semin Liver
Dis. 2013;33:380–8.
17. Beigneux AP, Davies BS, Gin P, et al. Glycosylphosphatidylinositol-
anchored high-density lipoprotein-binding protein 1 plays a critical
role in the lipolytic processing of chylomicrons. Cell Metab. 2007;5:
279–91.
18. Goulbourne CN, Gin P, Tatar A, et al. The GPIHBP1-LPL complex
is responsible for themargination of triglyceride-rich lipoproteins in
capillaries. Cell Metab. 2014;19:849–60.
19. Davies BS, Beigneux AP, Barnes 2nd RH, et al. GPIHBP1 is re-
sponsible for the entry of lipoprotein lipase into capillaries. Cell
Metab. 2010;12:42–52.
20. Fruchart JC, Staels B, Duriez P. PPARS, metabolic disease and
atherosclerosis. Pharmacol Res. 2001;44:345–52.
21. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha
and PPARgamma activators direct a distinct tissue-specific tran-
scriptional response via a PPRE in the lipoprotein lipase gene.
EMBO J. 1996;15:5336–48.
22. Caussy C, Charriere S, Meirhaeghe A, et al. Multiple microRNA
regulation of lipoprotein lipase gene abolished by 3’UTR polymor-
phisms in a triglyceride-lowering haplotype harboring p.Ser474Ter.
Atherosclerosis. 2016;246:280–6.
23. Ahn J, Lee H, Chung CH, Ha T. High fat diet induced
downregulation of microRNA-467b increased lipoprotein li-
pase in hepatic steatosis. Biochem Biophys Res Commun.
2011;414:664–9.
24. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J
Physiol Endocrinol Metab. 2009;297:E271–288.
25. Kersten S. Physiological regulation of lipoprotein lipase. Biochim
Biophys Acta. 1841;2014:919–33.
26. Surendran RP, Visser ME, Heemelaar S, et al. Mutations in LPL,
APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe
hypertriglyceridaemia. J Intern Med. 2012;272:185–96.
27. LaRosa JC, Levy RI, Herbert P, et al. A specific apoprotein activa-
tor for lipoprotein lipase. Biochem Biophys Res Commun.
1970;41:57–62.
28. Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS. A review of
the role of apolipoprotein C-II in lipoprotein metabolism and car-
diovascular disease. Metabolism. 2012;61:906–21.
29. Meyers NL, Larsson M, Olivecrona G, Small DM. A pressure-
dependent model for the regulation of lipoprotein lipase by apoli-
poprotein C-II. J Biol Chem. 2015;290:18029–44.
30. Amar MJ, Sakurai T, Sakurai-Ikuta A, et al. A novel apolipoprotein
C-II mimetic peptide that activates lipoprotein lipase and decreases
serum triglycerides in apolipoprotein E-knockout mice. J
Pharmacol Exp Ther. 2015;352:227–35.
31. Sakurai T, Sakurai A, Vaisman BL et al. Creation of ApoC-II mu-
tant mice and correction of their hypertriglyceridemia with an
ApoC-II mimetic peptide. J Pharmacol Exp Ther. 2016;356:341–
353.
32. Sparks JD, Dong HH. FoxO1 and hepatic lipid metabolism. Curr
Opin Lipidol. 2009;20:217–26.
33. Sacks FM. The crucial roles of apolipoproteins E and C-III in apoB
lipoprotein metabolism in normolipidemia and hypertriglyc-
eridemia. Curr Opin Lipidol. 2015;26:56–63.
34. Holleboom AG, Karlsson H, Lin RS, et al. Heterozygosity for a
loss-of-function mutation in GALNT2 improves plasma triglycer-
ide clearance in man. Cell Metab. 2011;14:811–8.
35. Pollin TI, Damcott CM, Shen H, et al. A null mutation in human
APOC3 confers a favorable plasma lipid profile and apparent
cardioprotection. Science. 2008;322:1702–5.
36. Crawford DC, Dumitrescu L, Goodloe R, et al. Rare variant
APOC3 R19X is associated with cardio-protective profiles in a
diverse population-based survey as part of the Epidemiologic
Architecture for Genes Linked to Environment Study. Circ
Cardiovasc Genet. 2014;7:848–53.
37. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-
Hansen A. Loss-of-function mutations in APOC3 and risk of ische-
mic vascular disease. N Engl J Med. 2014;371:32–41.
38. TG, HDLWorking Group of the Exome Sequencing Project NHL,
Blood I, et al. Loss-of-function mutations in APOC3, triglycerides,
and coronary disease. N Engl J Med. 2014;371:22–31.
39. Natarajan P, Kohli P, Baber U, et al. Association of APOC3 loss-of-
function mutations with plasma lipids and subclinical atherosclero-
sis: TheMulti-Ethnic BioImage Study. J AmColl Cardiol. 2015;66:
2053–5.
40. Mendivil CO, Zheng C, Furtado J, et al. Metabolism of very-low-
density lipoprotein and low-density lipoprotein containing apolipo-
protein C-III and not other small apolipoproteins. Arterioscler
Thromb Vasc Biol. 2010;30:239–45.
41. Larsson M, Vorrsjo E, Talmud P, et al. Apolipoproteins C-I and C-
III inhibit lipoprotein lipase activity by displacement of the enzyme
from lipid droplets. J Biol Chem. 2013;288:33997–4008.
42. Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the
familial chylomicronemia syndrome.NEngl JMed. 2014;371:2200–6.
43. Ginsberg HN, Brown WV. Apolipoprotein CIII: 42 years old and
even more interesting. Arterioscler Thromb Vasc Biol. 2011;31:
471–3.
44. Dallinga-Thie GM, van Tol A, Hattori H, et al. Plasma apolipopro-
tein A5 and triglycerides in type 2 diabetes. Diabetologia. 2006;49:
1505–11.
45. Do R, Stitziel NO,WonHH, et al. Exome sequencing identifies rare
LDLR and APOA5 alleles conferring risk for myocardial infarc-
tion. Nature. 2015;518:102–6.
46. Johansen CT,Wang J, Lanktree MB, et al. Excess of rare variants in
genes identified by genome-wide association study of hypertriglyc-
eridemia. Nat Genet. 2010;42:684–7.
47. Schaap FG, Nierman MC, Berbee JF, et al. Evidence for a complex
relationship between apoA-V and apoC-III in patients with severe
hypertriglyceridemia. J Lipid Res. 2006;47:2333–9.
48. Vaessen SF, Schaap FG, Kuivenhoven JA, et al. Apolipoprotein A-
V, triglycerides and risk of coronary artery disease: the prospective
Epic-Norfolk Population Study. J Lipid Res. 2006;47:2064–70.
49. Sharma V, Forte TM, Ryan RO. Influence of apolipoprotein A-Von
the metabolic fate of triacylglycerol. Curr Opin Lipidol. 2013;24:
153–9.
50. Shu X, Nelbach L, Weinstein MM, et al. Intravenous injection of
apolipoprotein A-V reconstituted high-density lipoprotein de-
creases hypertriglyceridemia in apoav−/− mice and requires
Curr Cardiol Rep (2016) 18: 67 Page 7 of 9 67
glycosylphosphatidylinositol-anchored high-density lipoprotein-
binding protein 1. Arterioscler ThrombVasc Biol. 2010;30:2504–9.
51. Gin P, Beigneux AP, Voss C, et al. Binding preferences for
GPIHBP1, a glycosylphosphatidylinositol-anchored protein of cap-
illary endothelial cells. Arterioscler Thromb Vasc Biol. 2011;31:
176–82.
52. Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in
angiogenesis and metabolism. Trends Cardiovasc Med. 2008;18:6–14.
53. Nidhina Haridas PA, Soronen J, Sadevirta S, et al. Regulation of
angiopoietin-like proteins (ANGPTLs) 3 and 8 by insulin. J Clin
Endocrinol Metab. 2015;100:E1299–1307.
54. Sukonina V, Lookene A, Olivecrona T, Olivecrona G. Angiopoietin-
like protein 4 converts lipoprotein lipase to inactive monomers and
modulates lipase activity in adipose tissue. Proc Natl Acad Sci U S
A. 2006;103:17450–5.
55. Lafferty MJ, Bradford KC, Erie DA, Neher SB. Angiopoietin-like
protein 4 inhibition of lipoprotein lipase: evidence for reversible
complex formation. J Biol Chem. 2013;288:28524–34.
56. Chi X, Shetty SK, Shows HW, et al. Angiopoietin-like 4 modifies
the interactions between lipoprotein lipase and its endothelial cell
transporter GPIHBP1. J Biol Chem. 2015;290:11865–77.
57. Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing,
ANGPTL3 mutations, and familial combined hypolipidemia. N
Engl J Med. 2010;363:2220–7.
58. Fu Z, Yao F, Abou-Samra AB, Zhang R. Lipasin, thermo-
regulated in brown fat, is a novel but atypical member of
the angiopoietin-like protein family. Biochem Biophys Res
Commun. 2013;430:1126–31.
59. Quagliarini F, Wang Y, Kozlitina J, et al. Atypical angiopoietin-like
protein that regulates ANGPTL3. Proc Natl Acad Sci USA.
2012;109:19751–6.
60. Hiukka A, Fruchart-Najib J, Leinonen E, et al. Alterations of lipids
and apolipoprotein CIII in very low density lipoprotein subspecies
in type 2 diabetes. Diabetes. 2005;48:1207–15.
61. Taskinen MR, Adiels M, Westerbacka J, et al. Dual meta-
bolic defects are required to produce hypertriglyceridemia in
obese subjects. Arterioscler Thromb Vasc Biol. 2011;31:
2144–50.
62. Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the geno-
mic era: a new paradigm. Endocr Rev. 2015;36:131–47.
63. Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of
very low-density lipoproteins is the hallmark of the dyslipidemia in
the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:
1225–36.
64. Adiels M, Taskinen MR, Packard C, et al. Overproduction of large
VLDL particles is driven by increased liver fat content in man.
Diabetologia. 2006;49:755–65.
65. Adiels M, Westerbacka J, Soro-Paavonen A, et al. Acute
suppression of VLDL1 secretion rate by insulin is associated
with hepatic fat content and insulin resistance. Diabetologia.
2007;50:2356–65.
66. Boren J,Watts GF, Adiels M, et al. Kinetic and related determinants
of plasma triglyceride concentration in abdominal obesity:
Multicenter Tracer Kinetic Study. Arterioscler Thromb Vasc Biol.
2015;35:2218–24.
67.• Taskinen MR, Boren J. New insights into the pathophysiology of
dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239:483–95.
Excellent review on the underlying pathophysiology of the dys-
lipidemia in type 2 diabetes mellitus.
68. Taskinen MR, Adiels M, Westerbacka J, et al. Dual meta-
bolic defects are required to produce hypertriglyceridemia in
obese subjects. Arterioscler Thromb Vasc Biol. 2011;31:
2144–50.
69. Norata GD, Tsimikas S, Pirillo A, Catapano AL. Apolipoprotein C-
III: from pathophysiology to pharmacology. Trends Pharmacol Sci.
2015;36:675–87.
70. Ginsberg HN, Le NA, Goldberg IJ, et al. Apolipoprotein B metab-
olism in subjects with deficiency of apolipoproteins CIII and AI.
Evidence that apolipoprotein CIII inhibits catabolism of
triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin
Invest. 1986;78:1287–95.
71. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester
transfer protein: at the heart of the action of lipid-modulating ther-
apy with statins, fibrates, niacin, and cholesteryl ester transfer pro-
tein inhibitors. Eur Heart J. 2010;31:149–64.
72. Fogelstrand P, Boren J. Retention of atherogenic lipoproteins in the
artery wall and its role in atherogenesis. Nutr Metab Cardiovasc
Dis. 2012;22:1–7.
73. Bartels ED, Christoffersen C, Lindholm MW, Nielsen LB. Altered
metabolism of LDL in the arterial wall precedes atherosclerosis
regression. Circ Res. 2015;117:933–42.
74. Armstrong SM, Sugiyama MG, Fung KY, et al. A novel assay
uncovers an unexpected role for SR-BI in LDL transcytosis.
Cardiovasc Res. 2015;108:268–77.
75. Frank PG, Pavlides S, Cheung MW, et al. Role of caveolin-1 in the
regulation of lipoprotein metabolism. Am J Physiol Cell Physiol.
2008;295:C242–248.
76. Boren J, Matikainen N, Adiels M, Taskinen MR. Postprandial
hypertriglyceridemia as a coronary risk factor. Clin Chim Acta.
2014;431:131–42.
77. Boren J, Taskinen MR, Olofsson SO, Levin M. Ectopic lipid stor-
age and insulin resistance: a harmful relationship. J Intern Med.
2013;274:25–40.
78. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial reten-
tion of atherogenic lipoproteins in early atherosclerosis. Nature.
2002;417:750–4.
79. Flood C, Gustafsson M, Pitas RE, et al. Molecular mechanism for
changes in proteoglycan binding on compositional changes of the
core and the surface of low-density lipoprotein-containing human
apolipoprotein B100. Arterioscler Thromb Vasc Biol. 2004;24:
564–70.
80. Flood C, Gustafsson M, Richardson PE, et al. Identification of the
proteoglycan binding site in apolipoprotein B48. J Biol Chem.
2002;277:32228–33.
81. Boren J, Olin K, Lee I, et al. Identification of the principal
proteoglycan-binding site in LDL. A single-point mutation in
apo-B100 severely affects proteoglycan interaction without affect-
ing LDL receptor binding. J Clin Invest. 1998;101:2658–64.
82. Zilversmit DB. A proposal linking atherogenesis to the interaction
of endothelial lipoprotein lipase with triglyceride-rich lipoproteins.
Circ Res. 1973;33:633–8.
83. Zilversmit DB. Atherogenesis: a postprandial phenomenon.
Circulation. 1979;60:473–85.
84. Cohn JS, Johnson EJ, Millar JS, et al. Contribution of apoB-48 and
apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial in-
creases in the plasma concentration of TRL triglycerides and retinyl
esters. J Lipid Res. 1993;34:2033–40.
85. Karpe F, Bell M, Bjorkegren J, Hamsten A. Quantification of post-
prandial triglyceride-rich lipoproteins in healthy men by retinyl es-
ter labeling and simultaneous measurement of apolipoproteins B-48
and B-100. Arterioscler Thromb Vasc Biol. 1995;15:199–207.
86. Schneeman BO, Kotite L, Todd KM, Havel RJ. Relationships be-
tween the responses of triglyceride-rich lipoproteins in blood plas-
ma containing apolipoproteins B-48 and B-100 to a fat-containing
meal in normolipidemic humans. Proc Natl Acad Sci U S A.
1993;90:2069–73.
87. Adiels M, Matikainen N, Westerbacka J, et al. Postprandial
accumulation of chylomicrons and chylomicron remnants is
determined by the clearance capacity. Atherosclerosis.
2012;222:222–8.
88. Moreton JR. Atherosclerosis and alimentary hyperlipidemia.
Science. 1947;106:190–1.
67 Page 8 of 9 Curr Cardiol Rep (2016) 18: 67
89. Moreton JR. Physical state of lipids and foreign substances produc-
ing atherosclerosis. Science. 1948;107:371–3.
90. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG.
Nonfasting triglycerides and risk of ischemic stroke in the general
population. JAMA. 2008;300:2142–52.
91. Beltran-Sanchez H, Harhay MO, Harhay MM, McElligott S.
Prevalence and trends of metabolic syndrome in the adult U.S.
population, 1999–2010. J Am Coll Cardiol. 2013;62:697–703.
92. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines
for the management of dyslipidaemias: the Task Force for the
management of dyslipidaemias of the European Society of
Cardiology (ESC) and the European Atherosclerosis Society
(EAS). Eur Heart J. 2011;32:1769–818.
93. Cohen JC, Stender S, Hobbs HH. APOC3, coronary disease, and
complexities of Mendelian randomization. Cell Metab. 2014;20:
387–9.
94. Graham MJ, Lee RG, Bell 3rd TA, et al. Antisense oligonucleotide
inhibition of apolipoprotein C-III reduces plasma triglycerides in
rodents, nonhuman primates, and humans. Circ Res. 2013;112:
1479–90.
Curr Cardiol Rep (2016) 18: 67 Page 9 of 9 67
